Your browser is no longer supported. Please, upgrade your browser.
Settings
VKTX Viking Therapeutics, Inc. daily Stock Chart
VKTX [NASD]
Viking Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.83 Insider Own0.30% Shs Outstand27.50M Perf Week31.58%
Market Cap82.50M Forward P/E- EPS next Y-0.80 Insider Trans0.00% Shs Float18.46M Perf Month141.94%
Income-17.80M PEG- EPS next Q-0.20 Inst Own5.70% Short Float1.73% Perf Quarter158.62%
Sales- P/S- EPS this Y75.40% Inst Trans0.64% Short Ratio0.64 Perf Half Y115.83%
Book/sh0.34 P/B8.82 EPS next Y3.60% ROA-91.30% Target Price7.33 Perf Year160.87%
Cash/sh0.45 P/C6.65 EPS next 5Y40.00% ROE-152.70% 52W Range0.88 - 3.24 Perf YTD152.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-11.22% Beta-
Dividend %- Quick Ratio4.30 Sales past 5Y- Gross Margin- 52W Low226.87% ATR0.28
Employees4 Current Ratio4.30 Sales Q/Q- Oper. Margin- RSI (14)76.20 Volatility20.31% 15.61%
OptionableNo Debt/Eq0.49 EPS Q/Q41.30% Profit Margin- Rel Volume3.53 Prev Close3.00
ShortableYes LT Debt/Eq0.49 EarningsNov 09 AMC Payout- Avg Volume496.61K Price2.88
Recom2.00 SMA2037.34% SMA5090.85% SMA200114.40% Volume971,644 Change-4.12%
Jul-17-17Reiterated H.C. Wainwright Buy $5 → $7
Aug-11-16Reiterated Laidlaw Buy $20 → $10
May-24-16Initiated Maxim Group Buy $5
Apr-07-16Initiated H.C. Wainwright Buy $6
Oct-23-17 07:05AM  Viking Therapeutics Presents Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 87th Annual Meeting of the American Thyroid Association PR Newswire
Oct-11-17 11:30AM  VKTX: KOLs Highlight Necessity For Effective Hip Fracture Treatment Zacks Small Cap Research
Oct-04-17 07:05AM  Viking Therapeutics Announces Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) PR Newswire +8.62%
Oct-02-17 07:20AM  Corporate News Blog - Viking Enters into Purchase Agreements worth $16.25 Million with Lincoln Park Capital ACCESSWIRE
Sep-29-17 07:05AM  Viking Therapeutics Announces Purchase Agreements for up to $16.25 Million with Lincoln Park Capital PR Newswire +6.11%
Sep-25-17 07:30AM  Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings PR Newswire +5.04%
Sep-21-17 06:21PM  Should You Buy Viking Therapeutics Inc (VKTX) Now? Simply Wall St.
Sep-12-17 11:00AM  VKTX: Encouraging In Vivo Data For VK2809 From Mouse Model of GSD 1a and Gene Expression Analysis in Mouse Model of NASH Zacks Small Cap Research +8.62%
Sep-11-17 07:05AM  Viking Therapeutics Announces Results of Gene Expression Analysis from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) PR Newswire
Sep-07-17 07:02AM  Viking Therapeutics Announces Presentation of Data from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) PR Newswire +6.67%
Sep-05-17 07:30AM  Viking Therapeutics to Present at Rodman & Renshaw's 19th Annual Global Investment Conference PR Newswire
Aug-14-17 04:00PM  VKTX: Data From Phase 2 Trial of VK5211 Expected in 4Q17 Zacks Small Cap Research
Aug-09-17 04:05PM  Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Aug-02-17 07:30AM  Viking Therapeutics to Report Financial Results for Second Quarter 2017 After Market Close on August 9, 2017 PR Newswire -9.71%
Jul-14-17 07:20AM  Corporate News Blog - Viking Therapeutics Completes Enrollment in Phase-2 study of VK5211 in Patients Recovering from Hip Fracture Accesswire
Jul-12-17 07:00AM  Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture PR Newswire
Jul-06-17 08:00AM  Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors PR Newswire
Jun-19-17 11:00AM  VKTX Raises $4.3 Million in Gross Proceeds From Registered Direct Offering Zacks Small Cap Research
Jun-14-17 09:55AM  Viking Therapeutics Announces $4.3 Million Registered Direct Offering PR Newswire -11.11%
Jun-08-17 08:15AM  Featured Company News - Viking Therapeutics' VK2809 Shows Encouraging Results in Non-Alcoholic Steatohepatitis Accesswire
Jun-07-17 01:00PM  VKTX: Potential of VK2809 in NASH Treatment Shown in Diet-Induced Mouse Model Zacks Small Cap Research
Jun-06-17 07:14AM  Viking Therapeutics Announces Promising Top Line Results from In Vivo Study of VK2809 in Non-Alcoholic Steatohepatitis (NASH) PR Newswire
May-31-17 07:30AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire
May-12-17 04:00PM  VKTX: Multiple Data Readouts Ahead in 2017 Zacks Small Cap Research -6.87%
May-10-17 04:05PM  Viking Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
May-03-17 07:30AM  Viking Therapeutics to Report Financial Results for First Quarter 2017 After Market Close on May 10, 2017 PR Newswire
Mar-28-17 07:30AM  Viking Therapeutics to Present at H.C. Wainwright & Co.'s 1st Annual NASH Investor Conference PR Newswire +8.20%
Mar-25-17 01:04PM  VIKING THERAPEUTICS, INC. Financials
Mar-24-17 11:45AM  VKTX: Results from Phase 2 Trial of VK5211 in Hip Fracture in mid-2017
Mar-21-17 04:16PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Viking Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q4 2016 Viking Therapeutics Inc Earnings Release - After Market Close
Mar-02-17 07:30AM  Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2016 After Market Close on March 21, 2017 PR Newswire -5.23%
Feb-28-17 07:30AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire
Feb-15-17 01:00PM  VKTX: Successful Preclinical Data for VK2809 in Glycogen Storage Disease 1a Zacks Small Cap Research +6.16%
Feb-14-17 06:25PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
07:05AM  Viking Therapeutics and PoC Capital Enter Agreement to Fund Clinical Development of VK2809 in Glycogen Storage Disease Ia (GSD Ia) PR Newswire
Feb-09-17 07:03AM  Viking Therapeutics Announces Initial Results from In Vivo Proof-of-Concept Study of VK2809 in Glycogen Storage Disease Ia (GSD Ia) PR Newswire -5.37%
Feb-07-17 07:30AM  Viking Therapeutics to Present at 2017 BIO CEO & Investor Conference PR Newswire +7.24%
Jan-05-17 04:48PM  Viking Therapeutics Announces Senior Level Appointments to Management Team PR Newswire
Dec-21-16 07:30AM  Viking Therapeutics to Present at Biotech Showcase 2017 PR Newswire -7.96%
Dec-06-16 04:05PM  Viking Therapeutics Receives Orphan Drug Designation for VK0214 from the U.S. Food and Drug Administration for the Treatment of X-Linked Adrenoleukodystrophy PR Newswire +10.00%
Nov-29-16 07:30AM  Viking Therapeutics to Present at the LD Micro Main Event PR Newswire
Nov-16-16 08:15AM  Blog Coverage Viking Presents New Clinical Data on VK2809 Accesswire
Nov-15-16 11:00AM  VKTX: Additional Data Show Promise of VK2809 in Lipid Disorders
07:02AM  Viking Therapeutics Presents New Clinical Data on VK2809 in Subjects with Elevated Cholesterol at American Heart Association Scientific Sessions 2016 PR Newswire
Nov-10-16 04:17PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and +16.00%
04:05PM  Viking Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
07:07AM  Q3 2016 Viking Therapeutics Inc Earnings Release - After Market Close
Nov-03-16 07:30AM  Viking Therapeutics to Host Conference Call to Discuss Third Quarter 2016 Financial Results PR Newswire -9.14%
Oct-13-16 07:30AM  Viking Therapeutics to Present at the 2016 BIO Investor Forum PR Newswire
Oct-04-16 07:16AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
07:05AM  Viking Therapeutics Doses First Patient in Phase 2 Clinical Trial of VK2809 in Patients with Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease PR Newswire
Sep-28-16 07:02AM  7 Stocks Under $10 That Could Make You a Lot of Money
Sep-27-16 12:30PM  VKTX: Encouraging Preclinical Data for VK0214 in Mouse Model of X-ALD
Sep-26-16 07:05AM  Viking Therapeutics Presents Positive Proof-of-Concept Data for VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) at the 86th Annual Meeting of the American Thyroid Association PR Newswire
Sep-19-16 04:31PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Sep-07-16 07:00AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire
Sep-01-16 07:30AM  Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016 PR Newswire
Aug-25-16 07:31AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
07:30AM  Viking Therapeutics Enters Into $12.5 Million Common Stock Purchase Agreement with Aspire Capital PR Newswire
Aug-16-16 12:00PM  VKTX: Data From Phase 2 Studies of VK2809 for Hypercholersterolemia and VK5211 for Hip Fracture to be Reported in 2Q17
Aug-11-16 04:20PM  VIKING THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
Aug-10-16 07:16AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
07:05AM  Viking Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
Jul-26-16 12:47PM  Heres Why Investors Are Watching Caterpillar, Sensata Technologies & Three Other Stocks at Insider Monkey +6.25%
08:25AM  Viking Therapeutics Gets Positive Top-Line Results From Proof-Of-Concept Trial Of VK0214
07:03AM  Viking Therapeutics Announces Positive Top-Line Results from Proof-of-Concept Study of VK0214 in In Vivo Model of X-Linked Adrenoleukodystrophy (X-ALD) PR Newswire
Jun-20-16 05:14PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
May-27-16 05:09PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-24-16 04:15PM  Viking Therapeutics to Present at the 2016 Marcum Microcap Conference PR Newswire
06:17AM  Coverage initiated on Viking Therapeutics by Maxim Group
May-16-16 04:00PM  VKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for Hypercholersterolemia to Commence in mid-2016
May-10-16 04:34PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and +7.63%
04:01PM  Viking Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update PR Newswire
May-02-16 07:46AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -9.66%
07:30AM  Viking Therapeutics Announces Full Exercise of Over-Allotment Option PR Newswire
Apr-21-16 11:17AM  5 Stocks Under $10 Set to Soar Higher at TheStreet
Apr-15-16 11:00AM  VKTX: Positive Phase 1b Data Presented for VK2809 in Hypercholestermic Patients; Recent M&A Activity Shows Viking is Significantly Undervalued
Apr-14-16 06:06AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
Apr-13-16 05:16PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -7.41%
05:00PM  Viking Therapeutics Announces Closing of Public Offering of Common Stock and Warrants PR Newswire
Apr-11-16 12:19PM  Viking Therapeutics (VKTX) Stock Rising on Positive Clinical Results at TheStreet +10.74%
12:06PM  Why These 5 Stocks Are Trending Ahead of Earnings Season Kickoff at Insider Monkey
10:41AM  Viking Therapeutics Gains 5% As Company Highlights Positive Data From A Phase 1b Clinical Trial
07:30AM  Viking Therapeutics Presents Positive Phase 1b Clinical Data on VK2809 in Hypercholesterolemic Subjects PR Newswire
Apr-08-16 09:00AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta -37.31%
08:30AM  Viking Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants PR Newswire
Apr-07-16 12:53PM  What You Need to Know About These Hot Stocks at Insider Monkey +34.97%
Mar-15-16 04:16PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
Mar-11-16 11:40AM  VKTX: Phase 2 Clinical Trial of VK2809 in Hypercholesterolemia to Initiate Mid-2016 -6.06%
Mar-08-16 04:19PM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Viking Therapeutics Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Corporate Update PR Newswire
Feb-02-16 07:30AM  Viking Therapeutics to Present at Upcoming Investor Conferences PR Newswire -8.38%
Jan-25-16 07:33AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
Jan-11-16 06:06AM  VIKING THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-07-16 07:30AM  Viking Therapeutics to Present at Biotech Showcase 2016 PR Newswire -6.52%
Dec-28-15 04:51PM  Viking Therapeutics Shares Double Amid No News +99.54%
Dec-08-15 10:30AM  VKTX: Additional Preclinical Data Shows Robust and Durable Weight Gain for VK5211-Treated Primates
Dec-07-15 07:30AM  Viking Therapeutics Presents New Data on VK5211 Demonstrating Robust Weight Gain in Primates Following 13 Weeks of Treatment PR Newswire
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease type Ia; and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy, a rare X-linked, inherited neurological disorder. In addition, it develops VK0612, an orally available drug candidate for the treatment of type 2 diabetes; small molecule agonists of the erythropoietin receptor for the treatment of anemia; and tissue-selective inhibitors of diacylglycerol acyltransferase-1 for the treatment of obesity and dyslipidemia. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOEHR MATTHEW WDirectorNov 15Buy1.2113,00015,67839,250Nov 15 04:34 PM